生物
细胞生物学
人口
细胞毒性T细胞
T细胞
转录因子
免疫学
CD8型
癌症研究
下调和上调
效应器
免疫系统
医学
遗传学
体外
基因
环境卫生
作者
Carlson Tsui,Lorenz Kretschmer,Svenja Rapelius,Sarah S. Gabriel,David Chisanga,Konrad Knöpper,Daniel T. Utzschneider,Simone Nüssing,Yang Liao,T. J. Mason,Santiago Valle Torres,Stephen Wilcox,Krystian Kanev,Sebastian Jarosch,Justin Leube,Stephen L. Nutt,Dietmar Zehn,Ian A. Parish,Wolfgang Kastenmüller,Wei Shi,Veit R. Buchholz,Axel Kallies
出处
期刊:Nature
[Nature Portfolio]
日期:2022-08-17
卷期号:609 (7926): 354-360
被引量:89
标识
DOI:10.1038/s41586-022-05105-1
摘要
CD8+ T cells that respond to chronic viral infections or cancer are characterized by the expression of inhibitory receptors such as programmed cell death protein 1 (PD-1) and by the impaired production of cytokines. This state of restrained functionality-which is referred to as T cell exhaustion1,2-is maintained by precursors of exhausted T (TPEX) cells that express the transcription factor T cell factor 1 (TCF1), self-renew and give rise to TCF1- exhausted effector T cells3-6. Here we show that the long-term proliferative potential, multipotency and repopulation capacity of exhausted T cells during chronic infection are selectively preserved in a small population of transcriptionally distinct CD62L+ TPEX cells. The transcription factor MYB is not only essential for the development of CD62L+ TPEX cells and maintenance of the antiviral CD8+ T cell response, but also induces functional exhaustion and thereby prevents lethal immunopathology. Furthermore, the proliferative burst in response to PD-1 checkpoint inhibition originates exclusively from CD62L+ TPEX cells and depends on MYB. Our findings identify CD62L+ TPEX cells as a stem-like population that is central to the maintenance of long-term antiviral immunity and responsiveness to immunotherapy. Moreover, they show that MYB is a transcriptional orchestrator of two fundamental aspects of exhausted T cell responses: the downregulation of effector function and the long-term preservation of self-renewal capacity.
科研通智能强力驱动
Strongly Powered by AbleSci AI